Suggestions
David Carter
Partner, CRG
David Carter is a Partner at CRG (Capital Resource Group) and a member of the company's Founders Group and Investment Committee.1 He joined CRG in 2003 and has over 30 years of experience in investment and advisory roles.1
Professional Background
David Carter's career at CRG involves:
- Leading due diligence efforts for investments in medical devices, specialty pharma, drug delivery, biopharma, and tools & diagnostic sectors1
- Sourcing, executing, and monitoring CRG investments1
- Staffing CRG deal teams1
Before joining CRG, Carter's professional journey included:
- Partner at Palestra Capital, a hedge fund focused on risk arbitrage and special situations1
- High yield analyst at Furman Selz LLC, covering healthcare-related high yield debt1
- Investment banking analyst in the Healthcare Group at Chemical Bank1
- Research assistant in the Mergers & Acquisitions Group of Morgan Stanley1
Education
David Carter's educational background includes:
- Bachelor of Science in finance from The Pennsylvania State University (1988)1
- Master of Arts degree in information science and systems from Columbia University (1994)1
- M.B.A. from Columbia University (1996)1
Achievements
Throughout his career, David Carter has closed over $5 billion in financing activity.1 He is based in Houston, Texas, and has a significant presence in the professional community with over 500 connections on LinkedIn.2
David Carter's expertise in healthcare investments and his long-standing role at CRG have positioned him as a key figure in the company's leadership and investment strategy.
Highlights
I recently spoke about the Future of #MedTech Innovation with @HOUBizJournal and discussed our significant experiences supporting entrepreneurs and executives of innovative commercial-staged companies. To-date we have committed $1 billion in the MedTech space across 20 investments, which helped these companies enhance their working capital, support product launch strategies and diversify capital structures. Enjoyed the discussions around bringing the latest next-gen products, technologies and services to help improve patient outcomes and lower overall healthcare costs https://bit.ly/2H2WhOs.
We’re pleased to see our portfolio company Neuropace and its management team demonstrate strong results in their next-generation epilepsy treatment. Neuropace’s RNS system, the world’s only brain-responsive neuromodulation system, results in significant seizure reduction and improved quality of life for epilepsy patients, according to the company’s groundbreaking 9-year study.
We are excited to continue working with Neuropace as they begin applying artificial intelligence to this rich data set, optimize therapy settings and improve clinical outcomes faster. Check out this NBC video to learn more about Neuropace’s important work: https://nbcnews.to/2FSDPda
